GlaxoSmithKline: Macular Degeneration trials
The registry lists 10 Macular Degeneration studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 5 have results posted.
Phase 1 5Phase 2 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)TerminatedNCT01362348Phase 2Results posted
- Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular DegenerationCompletedNCT01342926Phase 2Results posted
- Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular DegenerationCompletedNCT01134055Phase 2Results posted
- An Extension to Study MD7108240CompletedNCT00733304Phase 2Results posted
- To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMDCompletedNCT00612456Phase 2Results posted
- A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular DegenerationCompletedNCT01154062Phase 1
- A Safety Study to Evaluate Pazopanib Eye Drops in Healthy VolunteersCompletedNCT01072214Phase 1
- A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in HumansCompletedNCT01051700Phase 1
- Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye DropsCompletedNCT00659555Phase 1
- A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.CompletedNCT00463320Phase 1